CPSI VS INZY Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

CPSI
10/100

CPSI returned -59.89% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

INZY
100/100

INZY returned 60.67% in the last 12 months. Based on SPY's performance of 11.08%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

CPSI
52/100

11 analysts offer 12-month price targets for CPSI. Together, they have an average target of 0, the most optimistic target put CPSI at 0 within 12-months and the most pessimistic has CPSI at 0.

INZY

"Analyst Price Targets" not found for INZY

Technicals

CPSI
14/100

CPSI receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

INZY
10/100

INZY receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

CPSI
10/100

CPSI has missed earnings 8 times in the last 20 quarters.

INZY
67/100

INZY has missed earnings 2 times in the last 20 quarters.

Profit

CPSI
64/100

Out of the last 20 quarters, CPSI has had 18 profitable quarters and has increased their profits year over year on 7 of them.

INZY
10/100

Out of the last 19 quarters, INZY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

CPSI
31/100

CPSI has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.

INZY
47/100

INZY has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Dividend

CPSI
37/100

CPSI's most recent dividend was $0.10 per share, based on a share price of $11.36. It was a payout ratio of 18.57% compared to their total earnings.

INZY

"Dividend" not found for INZY

All score calculations are broken down here to help you make more informed investing decisions

Computer Programs & Systems In Summary

Nasdaq / CPSI
Healthcare
Health Information Services
Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital, and provide software applications. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions. It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.

Inozyme Pharma, Inc. Common Stock Summary

Nasdaq / INZY
Healthcare
Biotechnology
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.